N-(3-acetylphenyl)-2-(3,4,5-trimethoxyphenyl)acetamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-(3-acetylphenyl)-2-(3,4,5-trimethoxyphenyl)acetamide
• 化学式: C₁₉H₂₁NO₅
• 分子量: 343.4
• InChiKey: VSDSJNPJGCHCLB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  73.9
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Novel aromatic compounds and their use in medical applications
  申请人：Revotar Biopharmaceuticals AG

  公开号：EP1764093A1

  公开（公告）日：2007-03-21

  Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning -X- is e.g. or or or and Y being or or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds of formulas (Ia) or (Ib). The compounds are applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.

  含有至少一个式(Ia)或(Ib)化合物和一种药用载体的制药组合物，在药物中有用，其中符号和取代基的含义如下-X-为例如或或或和Y为或或上述式(Ia)或(Ib)化合物的药用盐、酯或酰胺以及前药。这些化合物用于调节由E-、P-或L-选择素结合介导的体外和体内结合过程。
• Novel Aromatic Compounds and Their Use in Medical Applications
  申请人：Aydt Ewald M.

  公开号：US20080207639A1

  公开（公告）日：2008-08-28

  Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier wherein the symbols have the following meaning —X— is e.g. and Y being e.g. or the pharmaceutically acceptable salts can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.

  药物组成物包括至少一种式(Ia)或(Ib)的化合物和药学上可接受的载体，其中符号的含义如下：-X-例如，Y为例如或药学上可接受的盐，可用于调节由E、P或L选择素结合介导的体外和体内结合过程。
• NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS
  申请人：AYDT Ewald M.

  公开号：US20110152291A1

  公开（公告）日：2011-06-23

  Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier wherein the symbols have the following meaning —X- is e.g. and Y being e.g. or the pharmaceutically acceptable salts can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.

  制药组合物包括至少一种式(Ia)或(Ib)的化合物和一种药学上可接受的载体，其中符号具有以下含义：-X-例如，Y为例如，或药学上可接受的盐可用于调节由E-、P-或L-选择素结合介导的体外和体内结合过程。
• US7923473B2
  申请人：——

  公开号：US7923473B2

  公开（公告）日：2011-04-12
• US8394835B2
  申请人：——

  公开号：US8394835B2

  公开（公告）日：2013-03-12